Agios to Participate in September Investor Conferences

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ: AGIO) announces its participation in two September investor conferences. The company will present at the Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET, followed by the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 4:50 p.m. ET. Live webcasts can be accessed on Agios' website, with replays available for two weeks post-event. Agios specializes in developing therapies for rare diseases, including a first-in-class treatment for pyruvate kinase deficiency and ongoing programs in various hematological conditions.

CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:

• Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 8:35 a.m. ET; and
• Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 4:50 p.m. ET.

Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare and genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com

Media:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com 

FAQ

When will Agios Pharmaceuticals present at the investor conferences in September 2022?

Agios Pharmaceuticals will present at the Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET, and at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 4:50 p.m. ET.

Where can I watch the Agios Pharmaceuticals conference presentations?

The presentations by Agios Pharmaceuticals can be accessed via live webcasts on the company's website under the 'Events & Presentations' section.

What is the focus of Agios Pharmaceuticals' therapies?

Agios Pharmaceuticals focuses on developing therapies for rare and genetically defined diseases, including treatments for conditions like pyruvate kinase deficiency and various types of anemia.

What type of therapy does Agios Pharmaceuticals offer for PK deficiency?

Agios Pharmaceuticals markets a first-in-class pyruvate kinase activator for adults with pyruvate kinase deficiency, the first disease-modifying therapy for this condition.

How long will webcasts of Agios Pharmaceuticals' presentations be available?

Replays of the webcasts for Agios Pharmaceuticals' presentations will be available for at least two weeks following each event.